drugset / Trial / NCT04335032
EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)
RandomizedParallel-groupTriple-blindTreatment
Summary
This is an double-blind, randomized, placebo controlled phase III study in hospitalized subjects with confirmed SARS-CoV-2.
Timeline
- Start
- 2021-01-08
- Primary completion
- 2021-11-30
- Completion
- 2021-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eicosapentaenoic acid | Small molecule | 1000 mg | — |